Compare Stocks: SLS, KRYS, ABVX, and PRAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$117.81 +2.6%	$126.47	$69.81 ▼ $148.83	$10.29B	0.96	1.43 million shs	765,364 shs
KRYS Krystal Biotech	$351.79 -1.8%	$349.42	$136.73 ▼ $382.54	$10.39B	0.54	333,914 shs	56,302 shs
PRAX Praxis Precision Medicines	$355.44 +1.0%	$338.95	$37.24 ▼ $392.70	$9.92B	2.76	459,673 shs	100,483 shs
SLS SELLAS Life Sciences Group	$14.28 +3.0%	$12.82	$1.39 ▼ $15.88	$2.87B	2.52	8.17 million shs	2.49 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	+2.74%	-12.33%	+11.75%	+30.40%
KRYS Krystal Biotech	0.00%	-0.31%	+9.74%	+15.65%	+138.40%
PRAX Praxis Precision Medicines	0.00%	+0.43%	-2.48%	+40.54%	+650.93%
SLS SELLAS Life Sciences Group	0.00%	+3.90%	+15.40%	+80.47%	+625.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$117.81 +2.6%	$126.47	$69.81 ▼ $148.83	$10.29B	0.96	1.43 million shs	765,364 shs
KRYS Krystal Biotech	$351.79 -1.8%	$349.42	$136.73 ▼ $382.54	$10.39B	0.54	333,914 shs	56,302 shs
PRAX Praxis Precision Medicines	$355.44 +1.0%	$338.95	$37.24 ▼ $392.70	$9.92B	2.76	459,673 shs	100,483 shs
SLS SELLAS Life Sciences Group	$14.28 +3.0%	$12.82	$1.39 ▼ $15.88	$2.87B	2.52	8.17 million shs	2.49 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	+2.74%	-12.33%	+11.75%	+30.40%
KRYS Krystal Biotech	0.00%	-0.31%	+9.74%	+15.65%	+138.40%
PRAX Praxis Precision Medicines	0.00%	+0.43%	-2.48%	+40.54%	+650.93%
SLS SELLAS Life Sciences Group	0.00%	+3.90%	+15.40%	+80.47%	+625.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.80	Moderate Buy	$156.50	32.84% Upside
KRYS Krystal Biotech	2.92	Moderate Buy	$365.40	3.87% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$585.95	64.85% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-29.97% Downside

Current Analyst Ratings Breakdown

Latest SLS, KRYS, ABVX, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/18/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/14/2026	KRYS Krystal Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$400.00
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00
8/7/2026	PRAX Praxis Precision Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$323.00 ➝ $362.00
8/6/2026	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$575.00 ➝ $582.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
KRYS Krystal Biotech	$389.13M	26.76	$7.16 per share	49.14	$42.06 per share	8.36
PRAX Praxis Precision Medicines	$8.55M	1,160.68	N/A	N/A	$34.85 per share	10.20
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.98	43.97	37.71	N/A	54.82%	19.34%	17.65%	11/2/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest SLS, KRYS, ABVX, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9585	N/A	N/A	N/A	$0.78 million	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	$1.79	+$0.09	$1.79	$120.93 million	$119.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
KRYS Krystal Biotech	N/A	8.32	7.96
PRAX Praxis Precision Medicines	N/A	15.73	15.73
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
KRYS Krystal Biotech	86.29%
PRAX Praxis Precision Medicines	67.84%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
KRYS Krystal Biotech	13.10%
PRAX Praxis Precision Medicines	3.00%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.25 million	N/A	Not Optionable
KRYS Krystal Biotech	210	29.60 million	25.72 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable

SLS, KRYS, ABVX, and PRAX Headlines

Recent News About These Companies

SELLAS Life Sciences Group, Inc. (SLS)

September 4, 2026 | finance.yahoo.com

Bank of New York Mellon Corp Makes New Investment in SELLAS Life Sciences Group, Inc. $SLS

September 4, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 3, 2026 | prnewswire.com

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

September 3, 2026 | finance.yahoo.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

September 2, 2026 | seekingalpha.com

Sellas gears up to present preclinical SLS009 data for pancreatic cancer at major oncology conference

September 2, 2026 | msn.com

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

September 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 1, 2026 | globenewswire.com

Why analysts think Sellas Life Sciences stock can gain 150% from here

September 1, 2026 | msn.com

Bank of America Corp DE Acquires 540,748 Shares of SELLAS Life Sciences Group, Inc. $SLS

September 1, 2026 | marketbeat.com

Sellas CEO Stergiou says ‘rigorous, unblinded’ data from pivotal AML trial will 'speak for itself' as REGAL catalyst nears

August 31, 2026 | msn.com

SLS stock looks like a $3 billion biotech winner—this short seller says the market has it dangerously wrong: 'Most expensive coin flip' (updated)

August 31, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's What Happened

August 28, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 8.8% - Still a Buy?

August 27, 2026 | marketbeat.com

Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline

August 26, 2026 | msn.com

Sellas Life Sciences: A LinkedIn Post Moves the Stock While the Official Filing Stays Silent

August 26, 2026 | ad-hoc-news.deA

SLS traders eye this important resistance zone ahead of key AML data readout

August 24, 2026 | msn.com

SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress

August 24, 2026 | blockonomi.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.4% - Time to Sell?

August 24, 2026 | marketbeat.com

Quantinno Capital Management LP Takes $315,000 Position in SELLAS Life Sciences Group, Inc. $SLS

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Decibel Cannabis Company (OtherDBCCF) and SELLAS Life Sciences Group (SLS)

August 22, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLS, KRYS, ABVX, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

$117.81 +3.02 (+2.63%)

As of 12:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Krystal Biotech NASDAQ:KRYS

$351.79 -6.45 (-1.80%)

As of 12:00 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Praxis Precision Medicines NASDAQ:PRAX

$355.44 +3.63 (+1.03%)

As of 12:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

SELLAS Life Sciences Group NASDAQ:SLS

$14.28 +0.42 (+3.02%)

As of 12:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, KRYS, ABVX, and PRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, KRYS, ABVX, and PRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, KRYS, ABVX, and PRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLS, KRYS, ABVX, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

Krystal Biotech NASDAQ:KRYS

Praxis Precision Medicines NASDAQ:PRAX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLS, KRYS, ABVX, and PRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLS, KRYS, ABVX, and PRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLS, KRYS, ABVX, and PRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLS, KRYS, ABVX, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

Krystal Biotech NASDAQ:KRYS

Praxis Precision Medicines NASDAQ:PRAX

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools